Clinical Trials

564 enrolled

ER+ HER2- Advanced Breast Cancer

NCT04486352 2026-04-01

EndoMAP

148 enrolled

Endometrial Neoplasms

NCT05735080 2026-04-01

INX-315-01

150 enrolled

Breast Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms

NCT07209449 2026-03-18

A Study of Elacestrant Alone or in Combination With Abemaciclib in People With Endometrial Cancer

75 enrolled

Phase 2 Active not recruiting

Recurrence, Endometrial Neoplasms

NCT04931342 2026-03-10

BOUQUET

176 enrolled

Phase 2 Active not recruiting

Ovarian Neoplasms

NCT04393285 2026-03-09

Abemaciclib and Letrozole to Treat Endometrial Cancer

53 enrolled

Endometrial Neoplasms

NCT06366347 2026-02-11

ALPINE: Maintenance Letrozole/Abemaciclib

32 enrolled

Phase 2 Active not recruiting

Endometrial Neoplasms

NCT06630325 2026-01-07

A Precision Medicine Approach (SMMART-ACT) for the Treatment of Patients With Advanced Sarcoma, Prostate, Breast, Ovarian or Pancreatic Cancer

30 enrolled

GastrointestinalGenitourinaryGynecologic

Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms

NCT05867251 2025-11-19

Study of AVZO-021 in Patients With Advanced Solid Tumors

430 enrolled

Phase EARLY_PHASE1 Completed

Carcinoma, Ovarian Epithelial, Breast Neoplasms, Fallopian Tube Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT04049227 2025-10-20

Abemaciclib and Letrozole in Treating Patients With Endometrial Cancer

27 enrolled

Endometrial Endometrioid Adenocarcinoma

NCT04469764 2025-07-29

Abemaciclib for the Treatment of Recurrent Ovarian or Endometrial Cancer

32 enrolled

Fallopian Tube Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms

NCT03675893 2025-06-15

RESOLVE: Abemaciclib + Letrozole +/- Metformin, Zotatifin, or Gedatolisib in Endometrial or Low-Grade Serous Ovarian Cancer

180 enrolled

Phase 1 Active not recruiting

Ovarian Neoplasms, Endometrial Neoplasms

NCT04188548 2025-06-04

EMBER

500 enrolled

Breast Neoplasms, Endometrial Neoplasms

NCT06594679 2025-03-28

NICHOL

73 enrolled

Ovarian Neoplasms

NCT05872204 2025-03-19

ALEPRO

100 enrolled